.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the general public market.The Eli Lilly-partnered biotech intend to list on the Nasdaq under the symbolic representation “BIOA,” according to papers submitted with the Securities and also Swap Payment. The business has certainly not publicly discussed an anticipated financial quantity for the offering.The clinical-stage firm boasts lead applicant azelaprag, a by mouth provided little molecule slated to enter phase 2 testing in combination with semaglutide– offered through Novo Nordisk under trademark name Wegovy for fat loss– in the first one-half of following year. Semaglutide is also sold as Ozempic and Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is created to blend properly along with GLP-1 medicines, improving weight loss while preserving muscular tissue mass. The investigational medication was located to be well-tolerated one of 265 individuals across eight stage 1 tests, depending on to BioAge.Earlier, BioAge garnered the help of Lilly to run a test mixing azelaprag along with the Large Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetic issues as Mounjaro and Zepbound for fat burning. The companions are actually currently conducting a phase 2 trial of azelaprag and also tirzepatide, along with topline results assumed in the third fourth of 2025.The biotech is actually likewise preparing a the hormone insulin sensitiveness proof-of-concept test examining azelaprag as a monotherapy in the very first one-half of following year to support prospective indication development.
On top of that, the firm prepares to ask the FDA for permission in the 2nd one-half of 2025 to launch human screening for an NLRP3 prevention targeting metabolic ailments and also neuroinflammation.BioAge’s anticipated transfer to the general public market complies with a slight uptick in prepared biotech IPOs coming from Bicara Rehabs and Zenas Biopharma. Zooming out, the recent IPO yard is actually a “blended image,” with premium companies still debuting on the public markets, simply in minimized numbers, according to PitchBook.